Dabrafenib and its potential for the treatment of metastatic melanoma

References

• Balch CM Gershenwald JE Soong SJ Final version of 2009AJCC melanoma staging and classification J Clin Oncol 2009 27 36 6199 6206 19917835
   PubMed Web of Science ®Google Scholar
• Davies H Bignell GR Cox C Mutations of the BRAF gene in human cancer Nature 2002 417 6892 949 954 12068308
   PubMed Web of Science ®Google Scholar
• Hauschild A Grob JJ Demidov LV Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 2012 380 9839 358 365 22735384
   PubMed Web of Science ®Google Scholar
• Flaherty KT Puzanov I Kim KB Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 2010 363 9 809 819 20818844
   PubMed Web of Science ®Google Scholar
• Neagu M Constantin C Tanase C Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma Expert Rev Mol Diagn 2010 10 7 897 919 20964610
   PubMed Web of Science ®Google Scholar
• Hauschild A Agarwala SS Trefzer U Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 2009 27 17 2823 2830 19349552
   PubMed Web of Science ®Google Scholar
• Flaherty KT Lee SJ Schuchter LM Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract] J Clin Oncol 2010 28 15 Suppl Abstract 8511
   Web of Science ®Google Scholar
• Middleton MR Grob JJ Aaronson N Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 2000 18 1 158 166 10623706
   PubMed Web of Science ®Google Scholar
• Eggermont AM Schadendorf D Melanoma and immunotherapy Hematol Oncol Clin North Am 2009 23 3 547 564 ix x 19464602
   PubMed Web of Science ®Google Scholar
• Patel PM Suciu S Mortier L EORTC Melanoma Group Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032) Eur J Cancer 2011 47 10 1476 1483 21600759
   PubMed Web of Science ®Google Scholar
• Avril MF Aamdal S Grob JJ Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 2004 22 6 1118 1125 15020614
   PubMed Web of Science ®Google Scholar
• Atkins MB Lotze MT Dutcher JP High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 1999 17 7 2105 2116 10561265
   PubMed Web of Science ®Google Scholar
• Brose MS Volpe P Feldman M BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 2002 62 23 6997 7000 12460918
   PubMed Web of Science ®Google Scholar
• Wellbrock C Ogilvie L Hedley D V599EB-RAF is an oncogene in melanocytes Cancer Res 2004 64 7 2338 2342 15059882
   PubMed Web of Science ®Google Scholar
• Wu J Rosenbaum E Begum S Westra WH Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis Am J Dermatopathol 2007 29 6 534 537 18032947
   PubMed Web of Science ®Google Scholar
• Curtin JA Fridlyand J Kageshita T Distinct sets of genetic alterations in melanoma N Engl J Med 2005 353 20 2135 2147 16291983
   PubMed Web of Science ®Google Scholar
• Hacker E Hayward NK Dumenil T James MR Whiteman DC The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population J Invest Dermatol 2009 130 1 241 248 19571821
   PubMed Web of Science ®Google Scholar
• Houben R Becker JC Kappel A Constitutive activation of the RAS-RAF signaling pathway in metastatic melanoma is associated with poor prognosis J Carcinog 2004 3 1 6 15046639
   PubMedGoogle Scholar
• Liu W Kelly JW Trivett M Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma J Invest Dermatol 2006 127 4 900 905 17159915
   PubMed Web of Science ®Google Scholar
• Viros A Fridlyand J Bauer J Improving melanoma classification by integrating genetic and morphologic features PLoS Med 2008 5 6 e120 18532874
   PubMed Web of Science ®Google Scholar
• Thomas NE Edmiston SN Alexander A Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma Cancer Epidemiol Biomarkers Prev 2007 16 5 991 997 17507627
   PubMed Web of Science ®Google Scholar
• Long GV Menzies AM Nagrial AM Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 2011 29 10 1239 1246 21343559
   PubMed Web of Science ®Google Scholar
• Jakob JA Bassett RLJr Ng CS NRAS mutation status is an independent prognostic factor in metastatic melanoma Cancer 2012 118 16 4014 4023 22180178
   PubMed Web of Science ®Google Scholar
• Edlundh-Rose E Egyházi S Omholt K NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing Melanoma Res 2006 16 6 471 478 17119447
   PubMed Web of Science ®Google Scholar
• Omholt K Platz A Kanter L Ringborg U Hansson J NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin Cancer Res 2003 9 17 6483 6488 14695152
   PubMed Web of Science ®Google Scholar
• Vredeveld LC Possik PA Smit MA Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis Genes Dev 2012 26 10 1055 1069 22549727
   PubMed Web of Science ®Google Scholar
• Dhomen N Reis-Filho JS da Rocha Dias S Oncogenic BRAF induces melanocyte senescence and melanoma in mice Cancer Cell 2009 15 4 294 303 19345328
   PubMed Web of Science ®Google Scholar
• Zhuang D Mannava S Grachtchouk V C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells Oncogene 2008 27 52 6623 6634 18679422
   PubMed Web of Science ®Google Scholar
• Hodis E Watson IR Kryukov GV A landscape of driver mutations in melanoma Cell 2012 150 2 251 263 22817889
   PubMed Web of Science ®Google Scholar
• Moreau S Saiag P Aegerter P Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes Ann Surg Oncol Epub July 7, 2012
   Web of Science ®Google Scholar
• Brissy S Gaudy-Marqueste C Mallet S BRAF mutation as a pejorative marker in metastatic melanoma [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8555
   Web of Science ®Google Scholar
• Rutkowski P Jurkowska M Gos A Correlations of molecular alterations in clinical stage III cutaneous melanoma with clinical-pathological features and patients outcome [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8548
   Web of Science ®Google Scholar
• Si L Kong Y Xu X Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort Eur J Cancer 2012 48 1 94 100 21788131
   PubMed Web of Science ®Google Scholar
• Menzies AM Haydu LE Visintin L Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma Clin Cancer Res 2012 18 12 3242 3249 22535154
   PubMed Web of Science ®Google Scholar
• Arkenau HT Kefford R Long GV Targeting BRAF for patients with melanoma Br J Cancer 2011 104 3 392 398 21139585
   PubMed Web of Science ®Google Scholar
• Ugurel S Thirumaran RK Bloethner S B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis PLoS One 2007 2 2 e236 17311103
   PubMed Web of Science ®Google Scholar
• Cheng S Chu P Hinshaw M Smith K Maize J Sferruzza A Frequency of mutations associated with targeted therapy in malignant melanoma patients [abstract] J Clin Oncol 2011 29 15 Suppl S549 Abstract 8597
   Web of Science ®Google Scholar
• Amanuel B Grieu F Kular J Millward M Iacopetta B Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region Pathology 2012 44 4 357 359 22614711
   PubMed Web of Science ®Google Scholar
• Bauer J Büttner P Murali R BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site Pigment Cell Melanoma Res 2011 24 2 345 351 21324100
   PubMed Web of Science ®Google Scholar
• Maldonado JL Fridlyand J Patel H Determinants of BRAF mutations in primary melanomas J Natl Cancer Inst 2003 95 24 1878 1890 14679157
   PubMed Web of Science ®Google Scholar
• Rimoldi D Salvi S Liénard D Lack of BRAF mutations in uveal melanoma Cancer Res 2003 63 18 5712 5715 14522889
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD Bezrookove V Green G Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi Nature 2009 457 7229 599 602 19078957
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD Griewank KG Crosby MB Mutations in GNA11 in uveal melanoma N Engl J Med 2010 363 23 2191 2199 21083380
   PubMed Web of Science ®Google Scholar
• Zhang J Yang PL Gray NS Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 2009 9 1 28 39 19104514
   PubMed Web of Science ®Google Scholar
• Wilhelm SM Carter C Tang L BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004 64 19 7099 7109 15466206
   PubMed Web of Science ®Google Scholar
• Eisen T Ahmad T Flaherty KT Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis Br J Cancer 2006 95 5 581 586 16880785
   PubMed Web of Science ®Google Scholar
• Flaherty KT Redlinger M Schuchter LM Lathia CD Weber BL O’Dwyer PJ Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma [abstract] J Clin Oncol 2005 23 16 Suppl Abstract 3037
   Google Scholar
• Flaherty KT Schiller J Schuchter LM A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel Clin Cancer Res 2008 14 15 4836 4842 18676756
   PubMed Web of Science ®Google Scholar
• Ott PA Hamilton A Min C A phase II trial of sorafenib in metastatic melanoma with tissue correlates PLoS One 2010 5 12 e15588 21206909
   PubMed Web of Science ®Google Scholar
• Stuart DD Aardalen KM Lorenzana EG Characterization of a novel RAF kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-RAF [abstract 4856] Proceedings of the 97th Annual Meeting of the American Association for Cancer Research April 5, 2006 Washington, DC Philadelphia, PA American Association for Cancer Research 2006
   Google Scholar
• Su Y Vilgelm AE Kelley MC RAF265 inhibits the growth of advanced human melanoma tumors Clin Cancer Res 2012 18 8 2184 2198 22351689
   PubMed Web of Science ®Google Scholar
• Sharfman WH Hodi FS Lawrence DP Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma [abstract] J Clin Oncol 2011 29 15 Suppl Abstract 8508
   Web of Science ®Google Scholar
• Bollag G Hirth P Tsai J Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010 467 7315 596 599 20823850
   PubMed Web of Science ®Google Scholar
• Falchook GS Long GV Kurzrock R Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 2012 379 9829 1893 1901 22608338
   PubMed Web of Science ®Google Scholar
• Anforth R Fernandez-Penas P Long GV Cutaneous toxicities of RAF inhibitors Lancet Oncol 2012
   Web of Science ®Google Scholar
• Halait H Demartin K Shah S Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma Diagn Mol Pathol 2012 21 1 1 8 22306669
   PubMedGoogle Scholar
• Anderson S Bloom KJ Vallera DU Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma Arch Pathol Lab Med 2012 136 11 1385 1391 22332713
   PubMed Web of Science ®Google Scholar
• Qu KZ Pan Q Zhang X Detection of BRAF mutations in melanoma: rate of mutation detection at codon 600 using Sanger sequencing as compared to the cobas 4800 method [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8596
   Web of Science ®Google Scholar
• Martin-Algarra S Labiano T Echeveste JI Use of cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM) [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8572
   Web of Science ®Google Scholar
• Sosman JA Kim KB Schuchter L Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 2012 366 8 707 714 22356324
   PubMed Web of Science ®Google Scholar
• Chapman PB Hauschild A Robert C BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 2011 364 26 2507 2516 21639808
   PubMed Web of Science ®Google Scholar
• Chapman PB Hauschild A Robert C Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8502
   Web of Science ®Google Scholar
• Eisenhauer EA Therasse P Bogaerts J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 2 228 247 19097774
   PubMed Web of Science ®Google Scholar
• Dummer R Goldinger SM Turtschi CP Open-label pilot study of vemurafenib in previously treated metastatic melanoma (mM) patients (pts) with symptomatic brain metastases (BM) [abstract] Ann Oncol 2012 23 ix366 Abstract 1125P
   Web of Science ®Google Scholar
• Laquerre S Arnone M Moss K A selective RAF kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RAFV600E mutation [abstract] Mol Cancer Ther 2009 8 12 Suppl 1 Abstract B88
   Web of Science ®Google Scholar
• Kefford R Arkenau H Brown MP Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract] J Clin Oncol 2010 28 15 Suppl S611 Abstract 8503
   Web of Science ®Google Scholar
• Kefford R Arkenau HT Brown M Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: evidence of clinical activity in subjects with metastatic melanoma [abstract] Pigment Cell Melanoma Res 2010 23 6 912 Abstract 929
   Google Scholar
• Therasse P Arbuck SG Eisenhauer EA New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 3 205 216 10655437
   PubMed Web of Science ®Google Scholar
• Trefzer U Minor DR Ribas A BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF (V600E/K)-positive metastatic melanoma [abstract] Pigment Cell Melanoma Res 2011 24 1020 Abstract LBA1021 1021
   Google Scholar
• Long GV Trefzer U Davies MA Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 study Lancet Oncol 2012 13 11 1087 1095 23051966
   PubMed Web of Science ®Google Scholar
• Gounder MM Spriggs DR Inclusion of patients with brain metastases in phase I trials: an unmet need Clin Cancer Res 2011 17 12 3855 3857 21527561
   PubMed Web of Science ®Google Scholar
• Raizer JJ Hwu WJ Panageas KS Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features Neuro Oncol 2008 10 2 199 207 18287337
   PubMed Web of Science ®Google Scholar
• Azer MWF Menzies AM Haydu L Kefford R Long GV Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436) [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8558
   Web of Science ®Google Scholar
• Agarwala SS Kirkwood JM Gore M Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study J Clin Oncol 2004 22 11 2101 2107 15169796
   PubMed Web of Science ®Google Scholar
• Davies MA Liu P McIntyre S Prognostic factors for survival in melanoma patients with brain metastases Cancer 2011 117 8 1687 1696 20960525
   PubMed Web of Science ®Google Scholar
• Carlino MS Fogarty GB Long GV Treatment of melanoma brain metastases: a new paradigm Cancer J 2012 18 2 208 212 22453023
   PubMed Web of Science ®Google Scholar
• Poulikakos PI Zhang C Bollag G Shokat KM Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 2010 464 7287 427 430 20179705
   PubMed Web of Science ®Google Scholar
• Heidorn SJ Milagre C Whittaker S Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010 140 2 209 221 20141835
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G Song K Yen I RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 2010 464 7287 431 435 20130576
   PubMed Web of Science ®Google Scholar
• Lacouture ME Chapman PB Ribas A Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy [abstract] J Clin Oncol 2011 29 15 Suppl Abstract 8520
   Web of Science ®Google Scholar
• Anforth R Tembe V Blumetti T Fernandez-Penas P Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors Pigment Cell Melanoma Res 2012 25 5 569 572 22726224
   PubMed Web of Science ®Google Scholar
• Su F Viros A Milagre C RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 2012 366 3 207 215 22256804
   PubMed Web of Science ®Google Scholar
• Oberholzer PA Kee D Dziunycz P RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J Clin Oncol 2012 30 3 316 321 22067401
   PubMed Web of Science ®Google Scholar
• Carlino MS Saunders CA Haydu LE (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma Eur J Cancer Epub September 13, 2012
   Web of Science ®Google Scholar
• McArthur GA Puzanov I Amaravadi R Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma J Clin Oncol 2012 30 14 1628 1634 22454415
   PubMed Web of Science ®Google Scholar
• Wilmott JS Tembe V Howle JR Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine Mol Cancer Ther Epub September 7, 2012
   Web of Science ®Google Scholar
• Rebecca VW Smalley KS Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma Expert Opin Investig Drugs 2011 20 2 137 140
   PubMed Web of Science ®Google Scholar
• Wilmott JS Long GV Howle JR Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 2012 18 5 1386 1394 22156613
   PubMed Web of Science ®Google Scholar
• Sosman JA Pavlick AC Schuchter LM Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 8503
   Web of Science ®Google Scholar
• McArthur GA Ribas A Chapman PB Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts) [abstract] J Clin Oncol 2011 29 15 Suppl Abstract 8502
   Web of Science ®Google Scholar
• Nathanson KL Martin A Letrero R Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436) [abstract] J Clin Oncol 2011 29 15 Suppl Abstract 8501
   Web of Science ®Google Scholar
• Smalley KS Lioni M Dalla Palma M Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol Cancer Ther 2008 7 9 2876 2883 18790768
   PubMed Web of Science ®Google Scholar
• Straussman R Morikawa T Shee K Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 2012 487 7408 500 504 22763439
   PubMed Web of Science ®Google Scholar
• Shi H Moriceau G Kong X Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nature Commun 2012 3 724 22395615
   PubMed Web of Science ®Google Scholar
• Poulikakos PI Persaud Y Janakiraman M RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 2011 480 7377 387 390 22113612
   PubMed Web of Science ®Google Scholar
• Villanueva J Vultur A Lee JT Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 2010 18 6 683 695 21156289
   PubMed Web of Science ®Google Scholar
• Montagut C Sharma SV Shioda T Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 2008 68 12 4853 4861 18559533
   PubMed Web of Science ®Google Scholar
• Nazarian R Shi H Wang Q Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 2010 468 7326 973 977 21107323
   PubMed Web of Science ®Google Scholar
• Wagle N Emery C Berger MF Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 2011 29 22 3085 3096 21383288
   PubMed Web of Science ®Google Scholar
• Johannessen CM Boehm JS Kim SY COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 2010 468 7326 968 972 21107320
   PubMed Web of Science ®Google Scholar
• Gramza AW Corless CL Heinrich MC Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors Clin Cancer Res 2009 15 24 7510 7518 20008851
   PubMed Web of Science ®Google Scholar
• Nguyen KS Kobayashi S Costa DB Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway Clin Lung Cancer 2009 10 4 281 289 19632948
   PubMed Web of Science ®Google Scholar
• Falchook GS Lewis KD Infante JR Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 2012 13 8 782 789 22805292
   PubMed Web of Science ®Google Scholar
• Kim KB Lewis KD Pavlick AC A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor [abstract] Pigment Cell Melanoma Res 2011 24 1021 Abstract LBA1021 1023
   Google Scholar
• Flaherty KT Robert C Hersey P METRIC Study Group Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 2012 367 2 107 114 22663011
   PubMed Web of Science ®Google Scholar
• Flaherty KT Infante JR Daud A Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 2012 367 18 1694 1703 23020132
   PubMed Web of Science ®Google Scholar
• Flaherty K Infante JR Falchook GS Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor [abstract] Pigment Cell Melanoma Res 2011 24 1022 Abstract LBA1021 1024
   Google Scholar
• Lee CI Menzies AM Haydu L Clements A Kefford R Long GV Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM) [abstract] J Clin Oncol 2012 30 15 Suppl Abstract e19011
   Web of Science ®Google Scholar
• Robert C Thomas L Bondarenko I Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 2011 364 26 2517 2526 21639810
   PubMed Web of Science ®Google Scholar
• Hodi FS O’Day SJ McDermott DF Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 363 8 711 723 20525992
   PubMed Web of Science ®Google Scholar
• Margolin K Ernstoff MS Hamid O Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 2012 13 5 459 465 22456429
   PubMed Web of Science ®Google Scholar
• Patnaik A Kang SP Tolcher AW Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract] J Clin Oncol 2012 30 15 Suppl Abstract 2512
   Google Scholar
• Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 26 2443 2454 22658127
   PubMed Web of Science ®Google Scholar
• Brahmer JR Tykodi SS Chow LQ Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 2012 366 26 2455 2465 22658128
   PubMed Web of Science ®Google Scholar
• Boni A Cogdill AP Dang P Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res 2010 70 13 5213 5219 20551059
   PubMed Web of Science ®Google Scholar
• Mocellin S Pasquali S Rossi CR Nitti D Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 2010 102 7 493 501 20179267
   PubMed Web of Science ®Google Scholar
• Petrella T Verma S Spithoff K Quirt I McCready D Melanoma Disease Site Group Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline Clin Oncol (R Coll Radiol) 2012 24 6 413 423 22245520
   PubMed Web of Science ®Google Scholar
• Hoeflich KP Herter S Tien J Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression Cancer Res 2009 69 7 3042 3051 19276360
   PubMed Web of Science ®Google Scholar
• Torti VR Wojciechowicz D Hu W Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901 Mol Cancer Ther 2012 11 10 2274 2283 22752429
   PubMed Web of Science ®Google Scholar
• Schwartz GK Robertson S Shen A A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors [abstract] J Clin Oncol 2009 27 15 Suppl Abstract 3513
   Google Scholar
• Ribas A Flaherty KT BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 2011 8 7 426 433 21606968
   PubMed Web of Science ®Google Scholar
• Hauschild A Grob JJ Demidov LV Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract] J Clin Oncol 2012 30 15 Suppl Abstract LBA8500
   Web of Science ®Google Scholar